TY - JOUR
T1 - Erratum
T2 - Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity (Cancer Cell (2019) 36(4) (444–457.e7), (S1535610819303848), (10.1016/j.ccell.2019.09.001))
AU - Robichaux, Jacqulyne Ponville
AU - Elamin, Yasir Y.
AU - Vijayan, R. S.K.
AU - Nilsson, Monique B.
AU - Hu, Lemei
AU - He, Junqin
AU - Zhang, Fahao
AU - Pisegna, Marlese
AU - Poteete, Alissa
AU - Sun, Huiying
AU - Li, Shuai
AU - Chen, Ting
AU - Han, Han
AU - Negrao, Marcelo Vailati
AU - Ahnert, Jordi Rodon
AU - Diao, Lixia
AU - Wang, Jing
AU - Le, Xiuning
AU - Meric-Bernstam, Funda
AU - Routbort, Mark
AU - Roeck, Brent
AU - Yang, Zane
AU - Raymond, Victoria M.
AU - Lanman, Richard B.
AU - Frampton, Garrett M.
AU - Miller, Vincent A.
AU - Schrock, Alexa B.
AU - Albacker, Lee A.
AU - Wong, Kwok kin
AU - Cross, Jason B.
AU - Heymach, John V.
N1 - Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2020/3/16
Y1 - 2020/3/16
N2 - Main Text (Cancer Cell 36, 444–457.e1–e7; October 14, 2019) In Figure 3E of the original article, the authors showed a western blot of different Ba/F3 cell lines expressing various HER2 exon 20 mutations. It was recently brought to the authors’ attention that there was an extra lane on the western blot and that the labels on the blot were unclearly labeled. The unintentional error was that the last lane of the western blot for HER2 (top row) contained a positive control cell line, H1781, with known expression of HER2 that was not cropped from the image, and the labels were shifted incorrectly. This error has now been corrected in the article online. While this correction does not affect the findings or the conclusions of the study, the authors would like to apologize for this error and any confusion that it may have caused for readers.
AB - Main Text (Cancer Cell 36, 444–457.e1–e7; October 14, 2019) In Figure 3E of the original article, the authors showed a western blot of different Ba/F3 cell lines expressing various HER2 exon 20 mutations. It was recently brought to the authors’ attention that there was an extra lane on the western blot and that the labels on the blot were unclearly labeled. The unintentional error was that the last lane of the western blot for HER2 (top row) contained a positive control cell line, H1781, with known expression of HER2 that was not cropped from the image, and the labels were shifted incorrectly. This error has now been corrected in the article online. While this correction does not affect the findings or the conclusions of the study, the authors would like to apologize for this error and any confusion that it may have caused for readers.
UR - http://www.scopus.com/inward/record.url?scp=85081135892&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081135892&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2020.03.003
DO - 10.1016/j.ccell.2020.03.003
M3 - Comment/debate
C2 - 32183953
AN - SCOPUS:85081135892
SN - 1535-6108
VL - 37
SP - 420
JO - Cancer cell
JF - Cancer cell
IS - 3
ER -